NLS Pharmaceutics AG
NLS Pharmaceutics AG (NLSP) Revenue
Annual & quarterly revenue history · segment & region breakdown
NLSP · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsNLS Pharmaceutics AG trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income NLS Pharmaceutics AG receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
NLS Pharmaceutics AG reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from NLS Pharmaceutics AG's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NLSP revenue · 4 questionsNLSP's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2024.
▸ Source: FMP · NLS Pharmaceutics AG SEC filings · GAAP · NLS Pharmaceutics AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026